All News
Avoid Abatacept in RA patients with a history of cancer?
The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of cancer with tofacitinib than with TNF inhibitors. In this setting, two posters both reassure and raise a new cause for concern.
Read Article
Do biologics help taper steroids in Adult Still’s Disease?
A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.
Read Article
Anifrolumab shows long-term promise in patients with lupus
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.
Read Article
Links:
Emerging and exciting treatments in RA: ACR22 preview
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.
Read Article
New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.
Read Article
AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.
Read Article
Update: axSpA Recommendations
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.
Read Article
Links:
Links:
EMA Crack Down on JAK Inhibitors
The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.
Read Article
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Read Article
Growing Confidence in Biosimilars?
Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends
Read Article
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis
On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.
Read Article